When was ViferaXS founded?

ViferaXS was founded in 2022 and raised its 1st funding round 4 years after it was founded.

Where is ViferaXS located?

ViferaXS is headquartered in Germany.

How many employees does ViferaXS have?

As of Sep 30, 2026, the latest employee count at ViferaXS is 2.

Is ViferaXS a funded company?

ViferaXS is a funded company, having raised a total of $13.7M across 2 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Sep 23, 2026.

When was the latest funding round of ViferaXS?

ViferaXS's latest funding was a $***** Series A round on Sep 23, 2026, with participation from 2 investors. Its primary sector is Oncology. In Germany, the Oncology sector has seen $78.5M in funding in 2026 to date.

Where does ViferaXS rank among its competitors?

ViferaXS ranks 1600th amongst 2504 active competitors, of which 835 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was ViferaXS, which secured $13.7M in Sep, 2026.

Who are the top competitors of ViferaXS?

ViferaXS's top competitors include Jazz Pharmaceuticals, Tango Therapeutics and Elicio. Among them, ViferaXS secured the most recent funding round in September, 2026.

ViferaXS - 2026 Company Profile, Funding & Competitors

Company Details

Developer of peptide based therapeutic vaccines for cancer treatment patients. This organization creates immunotherapies by identifying tumor specific antigens and utilizing adjuvant formulations to stimulate immune system T cell responses. The technology targets hematologic and solid tumors by designing off the shelf compositions. The process involves analyzing the immunopeptidome to generate treatments for clinical use.

Key Metrics

Founded Year

2022

Location

Germany

Stage

Series A

Total Funding

$13.7M in 2 rounds

Latest Funding Round

Series A, Sep 23, 2026, $*****

Investors

SPRIND & 1 more

Ranked

1600^th among 2504 active competitors

Employee Count

2 as on Sep 30, 2026

Similar Companies

VBI Vaccines & 40 more

View ViferaXS's full profile

ViferaXS has raised a total funding of $13.7M over 2 rounds. Its first funding round was on Sep 23, 2026. Its latest funding round was a Series A round on Sep 23, 2026 for $*****. 2 investors participated in its latest round. ViferaXS has 2 institutional investors.

Here is the list of recent funding rounds of ViferaXS:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 23, 2026	2849610	Series A	2436150	4368012	2770229	1021043
Sep 23, 2026	5833837	Grant (prize money)	1853094	6878698	4695800	SPRIND

Access funding benchmarks and valuations. Sign up today!

View details of ViferaXS's funding rounds and investors

ViferaXS's employee count trend

ViferaXS has 2 employees as of Sep 26. Here is ViferaXS's employee count trend over the years:

Uncover ViferaXS's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of ViferaXS include Jazz Pharmaceuticals, Tango Therapeutics and Elicio. Here is the list of Top 10 competitors of ViferaXS, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Tango Therapeutics 2017, Cambridge (United States), Public	Developer of drugs for the treatment of cancer	$165M	Boxer Capital, Casdin Capital & 8 others	72/100
3rd	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	72/100
4th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 22 others	71/100
5th	BioNTech 2008, Mainz (Germany), Public	Developer of immunotherapeutics for the treatment of cancer and other diseases	$861M	Fidelity Investments, Redmile Group & 28 others	71/100
6th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
7th	Deciphera 2003, Waltham (United States), Acquired	Developer of type 2 kinase inhibitors for treating cancer	$173M	Redmile Group, New Leaf Venture Partners & 4 others	70/100
8th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	70/100
9th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	69/100
10th	Halozyme 1999, San Diego (United States), Public	Developer of drug delivery technologies for the treatment of various diseases	-	Colt Ventures, BB Biotech & 8 others	69/100
1600th	ViferaXS 2022, Germany, Series A	Developer of peptide based therapeutic vaccines for cancer treatment patients	$13.7M	SPRIND, Huma	27/100